Clinical Trials for OSE Immunotherapeutics

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: OSE Immunotherapeutics

Clinical Trials (5)

NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
PHASE3Recruiting
363 participants
Started: Dec 3, 2024 · Completed: Dec 15, 2028
1 condition3 sponsors205 locations
NCT05751798
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
PHASE1/PHASE2Recruiting
41 participants
Started: Dec 20, 2022 · Completed: Dec 31, 2029
3 conditions1 sponsor10 locations
NCT04713514
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
PHASE2Active, not recruiting
180 participants
Started: Aug 5, 2021 · Completed: Dec 31, 2025
2 conditions3 sponsors40 locations
NCT04837092
Phase I/II Study of FR104 First Administration in Patient with Renal Transplantation: FIRsT Study
PHASE1/PHASE2Active, not recruiting
10 participants
Started: Jun 28, 2021 · Completed: Mar 31, 2025
1 condition2 sponsors1 location
NCT03806309
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
PHASE2Active, not recruiting
106 participants
Started: Apr 10, 2021 · Completed: Dec 31, 2025
3 conditions2 sponsors28 locations